Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

被引：0

作者：

Samoilova, Iuliia G. ^{[1
]}

Vaizova, Olga E. ^{[1
]}

Stankova, Anastasia E. ^{[1
]}

Matveeva, Mariia, V ^{[1
]}

Podchinenova, Daria, V ^{[1
,4
]}

Kudlay, Dmitry A. ^{[2
,3
]}

Borozinets, Anastasiia A. ^{[2
]}

Filippova, Tatyana A. ^{[1
]}

Grishkevich, Ivan R. ^{[1
]}

Partala, Anastasia, V ^{[1
]}

Gerasimova, Diana A. ^{[1
]}

机构：

[1] Siberia State Med Univ, Tomsk, Russia

[2] Sechenov First Moscow State Med Univ, Sechenov Moscow State Med Univ 1, Moscow, Russia

[3] Lomonosov Moscow State Univ, Moscow, Russia

[4] Inst Immunol, Natl Res Ctr, Moscow, Russia

来源：

TERAPEVTICHESKII ARKHIV | 2024年 / 96卷 / 01期

关键词：

polymorphism; dipeptidyl peptidase-4 inhibitors; type 2 diabetes mellitus; GLP1R; DPP-4; KCNQ1; GLYCEMIC RESPONSE; EPIDEMIOLOGY; GENE;

D O I：

10.26442/00403660.2024.01.202553

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase -4 inhibitor group. The literature was searched in the PubMed database from 2017 to 2023. Polymorphisms of several genes (GLP1R, TCF7L2, DPP -4, KCNQ1, KCNJ11, PNPLA3, PRKD1) are associated with the pharmacokinetic values and efficacy of dipeptidyl peptidase -4 inhibitors, which may be promising for personalizing the treatment of patients with type 2 diabetes mellitus.

引用

页码：63 / 67

页数：5

共 50 条

[21] Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
Karagiannis, Thomas
Paschos, Paschalis
Paletas, Konstantinos
Matthews, David R.
Tsapas, Apostolos
BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
[22] Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
Lin, Yi-Hsin
Huang, Hsuan
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2725 - 2733
[23] Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
Wei, Xin
Bai, Yu
Wang, Zhuo
Zheng, Xiaohong
Jin, Zening
Liu, Xin
DIABETOLOGY & METABOLIC SYNDROME, 2021, 13 (01):
[24] Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
Ametov, A. S.
Gusenbekova, D. G.
TERAPEVTICHESKII ARKHIV, 2014, 86 (08) : 85 - 89
[25] Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Health in Patients with Type 2 Diabetes Mellitus
Lee, Dong-Hwa
Kim, Kyong Young
Yoo, Min Young
Moon, Hansol
Ku, Eu Jeong
Oh, Tae Keun
Jeon, Hyun Jeong
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (20)
[26] Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus
Davidson, Michael H.
POSTGRADUATE MEDICINE, 2014, 126 (03) : 56 - 65
[27] Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
Yagi, Shusuke
Aihara, Ken-ichi
Akaike, Masashi
Fukuda, Daiju
Salim, Hotimah Masdan
Ishida, Masayoshi
Matsuura, Tomomi
Ise, Takayuki
Yamaguchi, Koji
Iwase, Takashi
Yamada, Hirotsugu
Soeki, Takeshi
Wakatsuki, Tetsuzo
Shimabukuro, Michio
Matsumoto, Toshio
Sata, Masataka
DIABETES & METABOLISM JOURNAL, 2015, 39 (04) : 342 - 347
[28] Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors
Yang, Tzu-Lin
Shen, Mei-Chiou
Yu, Ming-Lung
Huang, Yaw-Bin
Chen, Chung-Yu
JOURNAL OF FOOD AND DRUG ANALYSIS, 2016, 24 (02) : 450 - 454
[29] Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
Xin Wei
Yu Bai
Zhuo Wang
Xiaohong Zheng
Zening Jin
Xin Liu
Diabetology & Metabolic Syndrome, 13
[30] Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Mikhail, Nasser
POSTGRADUATE MEDICINE, 2012, 124 (04) : 138 - 144

← 1 2 3 4 5 →